Ankyra Therapeutics’ cANK-101 delivers promising preliminary data in canine melanoma trial
Ankyra Therapeutics, a biotech innovator, unveiled groundbreaking preliminary results from their exploratory Phase 1 canine clinical trial today. The trial, focused on their novel anchored ... Read More